BioMarin Q3 revenue rises on Amicus acquisition, adjusted EPS beats
Overview
Rare disease biotech's Q3 revenue rose 32% yr/yr, meeting analyst expectations
Adjusted EPS for Q3 beat analyst estimates
Growth driven by Amicus acquisition and higher demand for metabolic therapies
Outlook
BioMarin lowers 2026 revenue guidance to $3.8 bln-$3.9 bln from $3.875 bln-$3.925 bln
Company cuts 2026 non-GAAP diluted EPS forecast to $2.80-$3.10 from $4.90-$5.10
BioMarin cites order timing uncertainty and acquired IPR&D charges as reasons for revised outlook
Result Drivers
AMICUS ACQUISITION - Revenue growth was primarily driven by the addition of GALAFOLD and POMBILITI + OPFOLDA, acquired from Amicus Therapeutics in April 2026
METABOLIC CONDITIONS DEMAND - Higher patient numbers and increased VIMIZIM revenue contributed to 44% yr/yr growth in Metabolic Conditions segment
VOXZOGO PATIENT EXPANSION - VOXZOGO revenue rose 12% yr/yr, supported by a 17% increase in children treated globally
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Meet | $1.03 bln | $1.03 bln (25 Analysts) |
Q3 Adjusted EPS | Beat | $0.23 | $0.12 (19 Analysts) |
Q3 Loss Per Share | $0.63 | ||
Q3 Net Loss | $123 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for BioMarin Pharmaceutical Inc. is $89.66, about 53.2% above its October 30 closing price of $58.51
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 13 three months ago
Reuters Recommended Reads
Nov 2 - Krystal Biotech Q3 product revenue rises 30% on VYJUVEK demand
Nov 2 - Axsome Therapeutics Q3 revenue rises on Auvelity and Sunosi
Nov 2 - FDA to review uniQure's Huntington's gene therapy, decision due on May 2027
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)